Press Releases

In a Swedish video interview, Ziccum’s CEO Ann Gidner answers questions from analyst Jonathan Furelid on the topic of business dialogues and agreements. Apart from elaborating on the significance of the recently concluded Feasibility Study Agreement...

Vår VD Ann Gidner svarar på frågor om de uppdateringar bolaget delat gällande den växande portföljen av affärsdialoger den 11 juni, samt ett projektavtal som nu signerats, den 19 juni. Q: Ni kommunicerade den 19 juni...

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, HONG KONG, JAPAN, CANADA, NEW ZEALAND, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA, RUSSIA, BELARUS OR IN ANY OTHER...

Såsom publicerat 19 juni 2024, har Ziccum AB (publ) tecknat ett avtal med ReCode Therapeutics Inc. (ReCode) beträffande utvärdering av LaminarPace-teknologin. ReCode är ett amerikanskt läkemedelsbolag som utvecklar nästa...

Ziccum AB (publ) has signed an Evaluation Agreement with ReCode Therapeutics, Inc. (ReCode), a US clinical-stage genetic medicines company using tissue-specific delivery to power the next wave of mRNA and gene correction therapeutics, for evaluation of...

Ziccum is continuously engaged in business discussions with potential industrial partners. The status of Ziccum’s project portfolio is presented quarterly in the company interim reports. There are currently further updates to report. Several new...

On 27 April 2021, the Annual General Meeting of Ziccum AB (publ) ("Ziccum" or the "Company") resolved on a directed issue of not more than 46,000 employee stock options of series LTI 2021:1 (the "Stock Options") to certain...

The following resolutions were passed at the Annual General Meeting (the “AGM”) of Ziccum AB (publ) (the “Company”) on the 29th of May 2024 in Lund. Adoption of income statement and balance sheet and discharge from liabilityThe...

Ziccum AB (publ) (”Bolaget”) avhöll den 29 maj 2024 årsstämma i Lund. Vid stämman fattades bland annat följande beslut. Fastställande av årsbokslut och ansvarsfrihetStämman beslutade att fastställa...

Ziccum partners with Dagens Industri, the largest Nordic business paper, to improve shareholders’ access to news updates and raise broader awareness of its continuous scientific and commercial progress. Ziccum AB has signed a partnership with the...

Den 25 april 2024 offentliggjorde Ziccum AB (publ) (”Bolaget”) pressmeddelande innehållande kallelse till Bolagets årsstämma att hållas den 29 maj 2024. I kallelsen angavs att förslag avseende beslut enligt punkterna...

Watch Ziccum CEO Ann Gidner in a comprehensive interview with analyst Jonathan Furelid on the highlights of Ziccum’s Q1 2024 report and the company’s current and coming status. CEO Ann Gidner provides investors with updates and insights on...

Ziccum AB (publ) (‘Ziccum’) has filed three PCT applications with ample and significant data covering years of equipment development and refinement, process parameter knowledge gained, plus key biopharmaceutical formulation expertise established...

In addition to its existing network of high expertise suppliers and consultants, Ziccum has signed a long-term agreement with the GMP equipment specialist RFR Solutions, for the next phase in the industrialization and scale-out of the LaminarPaceTM equipment...

Aktieägarna i Ziccum AB (publ), org.nr 559107-9412, (”Bolaget”) kallas härmed till årsstämma den 29 maj 2024 kl. 15.00 i Bolagets lokaler på Scheelevägen 22 i Lund. Rösträttsregistrering startar kl...

Ziccum AB meddelar idag att bolagets årsredovisning för 2023 nu finns tillgänglig på bolagets hemsida www.ziccum.com. För att läsa hela rapporten, på svenska, vänligen besök: https://ziccum.com/investors/financial-reports/...

Ziccum today announces that its Annual Report for 2023 is now available on the company’s website www.ziccum.com. To read the Report in full (in Swedish) please visit here: https://ziccum.com/investors/financial-reports/ For more information about...

On Tuesday May 14th, in Park Avenue New York City, Ziccum CEO Ann Gidner will present at the first event on high-value biotech and biopharma disruptor technologies to be hosted by CapitalOne, one of the US’ largest bank corporations. She will present...

Ziccum is reorganizing its administrative functions, due to the increased amount of business dialogues and to perform financial reporting in a more streamlined fashion. Two new roles of Business & Project Manager and a business-oriented, junior Financial...